EPIDIOLEX® (cannabidiol) delivers broad-spectrum efficacy, significantly reducing multiple seizure types in LGS, Dravet syndrome, and TSC

Efficacy proven across 3 different epilepsies

LGS

Significant reductions in drop seizures and total seizures

Efficacy in LGS

Dravet syndrome

Significant reductions in convulsive seizures

Efficacy in Dravet syndrome

TSC

Significant reductions in TSC-associated partial-onset* and generalized seizures

Efficacy in TSC

*Partial-onset seizures (focal) included simple partial seizures (focal motor seizure), complex partial seizures (focal impaired), and secondary generalized tonic-clonic seizures (focal to bilateral tonic-clonic).1

EPIDIOLEX is the only FDA-approved cannabidiol

EPIDIOLEX for Patient with LGS | Woman playing guitar as a man smiles

Steven, at age 32 | EPIDIOLEX patient living with LGS

Steven, at age 32 | EPIDIOLEX patient living with LGS

  • Indicated to treat seizures associated with LGS, Dravet syndrome, and TSC in patients 1 year and older
  • Structurally distinct from other ASMs and the only ASM approved to treat seizures associated with LGS, Dravet syndrome, and TSC in children and adults
  • The precise mechanism of action of EPIDIOLEX is unknown. However, EPIDIOLEX is believed to exert its anticonvulsant effects through multiple modes of action
  • Offers flexible dosing for tolerability and response optimization
Learn more about dosing
Find insurance coverage

How is EPIDIOLEX different from non–FDA approved cannabidiol (CBD) products?

Eligible for insurance coverage

Derived from pesticide- and contaminant-free plants2

Quality standards for stability and consistency2

Highly controlled manufacturing2

No longer a federally scheduled drug

Efficacy, safety, and dosing established across multiple controlled studies

Graphics

EPIDIOLEX was studied in over 900 patients

living with LGS, Dravet syndrome, and TSC—making up the largest controlled clinical trial program for an ASM in these conditions to date.3†

Proven across a wide range of patients

and concomitant treatments, EPIDIOLEX can be used as a monotherapy or with other ASMs.

Sustained effects up to 3 years

in open-label extensions in LGS, Dravet syndrome, and TSC.4-6

†There was a second randomized controlled trial in 199 patients living with Dravet syndrome that has been completed since its original approval.3

Join the more than 7,000 prescribers who have treated more than 50,000 patients in the United States with EPIDIOLEX.2